KOLXITSINNI O‘Z ICHIGA OLGAN OPTIMALLASHTIRILGAN KO‘P KOMPONENTLI DORI TERAPIYASINING TERI ORQALI KORONAR ARALASHUVDAN KEYINGI BEMORLARDA STENOKARDIYA QAYTALANISHINI OLDINI OLISHDAGI AHAMIYATI
Maqola yon paneli
Maqola asosiy qismi
Abstrak
Ushbu maqolada muvaffaqiyatli teri orqali koronar aralashuvdan keyin ham qaytalanuvchi stenokardiya muhim klinik muammo bo‘lib qolayotgani yoritilgan. Prospektiv randomizatsiyalangan nazoratli tadqiqotga muvaffaqiyatli koronar aralashuvdan o‘tgan 120 nafar bemor kiritildi. Bemorlar har biri 60 nafardan iborat ikki guruhga ajratildi. Asosiy guruh standart terapiyaga qo‘shimcha ravishda kuniga 0,5 mg dozada kolxitsin qabul qildi, nazorat guruhi esa faqat standart terapiya oldi. Kuzatuv muddati 12 oy davom etdi. Birlamchi yakuniy ko‘rsatkich stenokardiya qaytalanish chastotasi bo‘ldi. Ikkilamchi ko‘rsatkichlar LDL-xolesterinning maqsadli darajasiga erishish, yallig‘lanish markerlari (yuqori sezgir CRP, IL-6) dinamikasi, hayot sifati va katta noxush yurak-qon tomir hodisalari chastotasini qamrab oldi. 12 oy yakunida stenokardiya qaytalanishi asosiy guruhda 7 nafar (11,7%) bemorda, nazorat guruhida esa 17 nafar (28,3%) bemorda kuzatildi. Kolxitsin qo‘shilgan terapiya yallig‘lanishni kamaytirish, lipid ko‘rsatkichlarini yaxshilash va hayot sifatini oshirish bilan birga kechdi. Tadqiqot natijalari past dozali kolxitsinni standart davolashga qo‘shish ChKVdan keyingi bemorlarda stenokardiya qaytalanishini kamaytirishi va uzoq muddatli prognozni yaxshilashi mumkinligini ko‘rsatdi.
Maqola tafsilotlari
##submission.citations##
Агабабян И. Р., Кобилова Н. А., Норматов О. С. У. Зависимость уровня нейтрофилов от состояния пародонта у больных хронической ишемической болезнью сердца //Journal of cardiorespiratory research. – 2023. – Т. 1. – №. 1. – С. 9-13.
Агабабян И. Р., Ярашева З. Х. Эхокардиография в прогнозировании ранней хронической сердечной недостаточности у больных пожилого возраста //Достижения науки и образования. – 2022. – №. 2 (82). – С. 103-108.
Ризаев Э. А., Агабабян И. Р., Арзикулова М. Ш. К. Аутоиммунное воспаление как причинно-следственная связь пародонтита и атеросклероза //Вопросы науки и образования. – 2022. – №. 6 (162). – С. 50-64.
De Luca L., Rosano G. M. C., Spoletini I. Post-percutaneous coronary intervention angina: From physiopathological mechanisms to individualized treatment //Cardiology Journal. – 2022. – Т. 29. – №. 5. – С. 850-857.
Deftereos S. G. et al. Colchicine in cardiovascular disease: in-depth review //Circulation. – 2022. – Т. 145. – №. 1. – С. 61-78.
Ford T. J., Berry C. Angina: contemporary diagnosis and management //Heart. – 2020. – Т.
Lombardi M. et al. Angina after percutaneous coronary interventions //European Heart Journal. – 2026. – Т. 47. – №. 4. – С. 408-422.
Nelson K., Fuster V., Ridker P. M. Low-dose colchicine for secondary prevention of coronary artery disease: JACC review topic of the week //Journal of the American College of Cardiology. – 2023. – Т. 82. – №. 7. – С. 648-660.
Niccoli G. et al. Angina after percutaneous coronary intervention: the need for precision medicine //International Journal of Cardiology. – 2017. – Т. 248. – С. 14-19.
Nidorf S. M. et al. Colchicine in patients with chronic coronary disease //New England journal of medicine. – 2020. – Т. 383. – №. 19. – С. 1838-1847.
Samuel M. et al. Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis //European heart journal. – 2025. – Т. 46. – №. 26. – С. 2552-2563.
Tardif J. C. et al. Efficacy and safety of low-dose colchicine after myocardial infarction //New England journal of medicine. – 2019. – Т. 381. – №. 26. – С. 2497-2505. Research Focus International Scientific Journal, Uzbekistan 275 https://refocus.uz/